0.61Open0.65Pre Close2 Volume25 Open Interest2.00Strike Price117.00Turnover111.74%IV2.40%PremiumDec 20, 2024Expiry Date0.50Intrinsic Value100Multiplier22DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type0.8320Delta0.3673Gamma4.35Leverage Ratio-0.0041Theta0.0009Rho3.62Eff Leverage0.0015Vega
Allogene Therapeutics Stock Discussion
07/11/2024 - 23:00
Phase 1 TRAVERSE Trial Demonstrated a Single Infusion of ALLO-316 Can Yield an Overall Response Rate of 50% and Confirmed Response Rate of 33% in Patients with CD70 Tumor Proportion Score (TPS) of Greater than 50%
TRAVERSE Trial Highlights the Ability of CD70 Dagger® Te...
3.20+
No comment yet